Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - fluoxetinhydroklorid - dispergerbar tablett - 20 mg - laktosmonohydrat hjälpämne; fluoxetinhydroklorid 22,4 mg aktiv substans - fluoxetin

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunsuppressiva - simulect är indicerat för profylax av akut organavstötning vid de-novo allogen renaltransplantation hos vuxna och barn (1-17 år). det används tillsammans med ciklosporin för microemulsion - och kortikosteroid-baserade immunosuppression, i patienter med panel reaktiv antikroppar mindre än 80%, eller i en trippel underhåll immunosuppressiva regim som innehåller ciklosporin för microemulsion, kortikosteroider och antingen azatioprin eller mykofenolatmofetil.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - fluoxetinhydroklorid - dispergerbar tablett - 20 mg - laktosmonohydrat hjälpämne; fluoxetinhydroklorid 22,4 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - abakavirsulfat; lamivudin - filmdragerad tablett - 600 mg/300 mg - lamivudin 300 mg aktiv substans; abakavirsulfat 702,762 mg aktiv substans; para-orange aluminiumlack hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - darunavirpropylenglykolsolvat - filmdragerad tablett - 600 mg - para-orange aluminiumlack hjälpämne; laktosmonohydrat hjälpämne; darunavirpropylenglykolsolvat 683,33 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - darunavirpropylenglykolsolvat - filmdragerad tablett - 400 mg - laktosmonohydrat hjälpämne; para-orange aluminiumlack hjälpämne; darunavirpropylenglykolsolvat 455,55 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - klopidogrelbesilat - filmdragerad tablett - 75 mg - klopidogrelbesilat 112,1 mg aktiv substans; mannitol hjälpämne; laktosmonohydrat hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 1 g - meropenemtrihydrat 1140 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medical valley invest ab - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - meropenemtrihydrat 570 mg aktiv substans